PP_1170x120_10-25-21

non-alcoholic steatohepatitis

Allergan announces pair of biopharma acquisitions

Allergan announces pair of biopharma acquisitions

DUBLIN, Ireland — Chalk up three acquisitions for Allergan plc in less than a week. On Tuesday, Allergan said it plans to purchase clinical-stage biopharmaceutical company Tobira Therapeutics Inc. in an agreement valued at up to $1.695 billion. South San Francisco-based Tobira focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and